<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32076756</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1433-0407</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Gene-specific treatment approaches in amyotrophic lateral sclerosis in the present and future].</ArticleTitle><Pagination><StartPage>287</StartPage><EndPage>293</EndPage><MedlinePgn>287-293</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00115-020-00873-5</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is monogenic in up to 10% of cases. Various mutation types result in a&#xa0;loss of function, a&#xa0;gain of toxicity or a&#xa0;combination of both. Due to the continuous development of gene-specific approaches, the treatment of the various ALS forms is no longer a&#xa0;dream. Depending on the underlying mutation type and pathomechanism, different antisense oligonucleotide (ASO)-based or viral strategies are available. The SOD1 and C9ORF72 genes are the most frequently mutated ALS genes in Germany and their mutations most likely predominantly lead to a&#xa0;gain of toxicity. For both genes, specific ASOs were developed binding to the respective mRNAs and leading to their degradation and are now being tested in clinical trials after excellent efficacy in the related ALS mouse models, with promising interim results. For the sporadic form of ALS there are also gene-specific approaches that compensate pathomechanisms and are a&#xa0;promising therapeutic option. In this article, gene-specific therapeutic developments in ALS as well as possible pitfalls and challenges are discussed in detail.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurologische Universit&#xe4;tsklinik, Universit&#xe4;ts- und Rehabilitationskliniken Ulm, Oberer Eselsberg&#xa0;45, 89081, Ulm, Deutschland. david.brenner@uni-ulm.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freischmidt</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurologische Universit&#xe4;tsklinik, Universit&#xe4;ts- und Rehabilitationskliniken Ulm, Oberer Eselsberg&#xa0;45, 89081, Ulm, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Neurologische Universit&#xe4;tsklinik, Universit&#xe4;ts- und Rehabilitationskliniken Ulm, Oberer Eselsberg&#xa0;45, 89081, Ulm, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>J H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Neurologische Universit&#xe4;tsklinik, Universit&#xe4;ts- und Rehabilitationskliniken Ulm, Oberer Eselsberg&#xa0;45, 89081, Ulm, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Genspezifische Therapieans&#xe4;tze bei amyotropher Lateralsklerose in Gegenwart und Zukunft.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antisense oligonucleotide</Keyword><Keyword MajorTopicYN="N">Gain of toxicity</Keyword><Keyword MajorTopicYN="N">Loss of function</Keyword><Keyword MajorTopicYN="N">Pathomechanisms</Keyword><Keyword MajorTopicYN="N">Viral strategies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32076756</ArticleId><ArticleId IdType="doi">10.1007/s00115-020-00873-5</ArticleId><ArticleId IdType="pii">10.1007/s00115-020-00873-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curr Opin Neurol. 2018 Oct;31(5):648-654</Citation><ArticleIdList><ArticleId IdType="pubmed">30028737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2013 Dec;9(12):708-14</Citation><ArticleIdList><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2019 Nov;138(5):813-826</Citation><ArticleIdList><ArticleId IdType="pubmed">31332509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2016 Jun 1;126(6):2249-53</Citation><ArticleIdList><ArticleId IdType="pubmed">27140399</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):245-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Endocrinol (Lausanne). 2018 Aug 03;9:402</Citation><ArticleIdList><ArticleId IdType="pubmed">30123182</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2018 Aug 1;128(8):3558-3567</Citation><ArticleIdList><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2013 Dec;21(12):2148-59</Citation><ArticleIdList><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2018 Sep;14(9):544-558</Citation><ArticleIdList><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2019 Aug 1;381(5):486-488</Citation><ArticleIdList><ArticleId IdType="pubmed">31314961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2019 Feb;22(2):167-179</Citation><ArticleIdList><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2016 Jun 15;35(12):1276-97</Citation><ArticleIdList><ArticleId IdType="pubmed">27103069</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurol. 2019 Oct;32(5):735-739</Citation><ArticleIdList><ArticleId IdType="pubmed">31335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):257-68</Citation><ArticleIdList><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Mol Med. 2016 Sep;22(9):769-783</Citation><ArticleIdList><ArticleId IdType="pubmed">27498188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2017 Sep 27;8(1):710</Citation><ArticleIdList><ArticleId IdType="pubmed">28955034</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):817-827</Citation><ArticleIdList><ArticleId IdType="pubmed">29650794</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2019 Mar 4;7(1):32</Citation><ArticleIdList><ArticleId IdType="pubmed">30832726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2016 Jan;79(1):152-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2016 May 4;90(3):535-50</Citation><ArticleIdList><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Eye (Lond). 2011 May;25(5):587-95</Citation><ArticleIdList><ArticleId IdType="pubmed">21562585</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2017 Apr 20;544(7650):367-371</Citation><ArticleIdList><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2019 Nov 5;93(19):e1748-e1755</Citation><ArticleIdList><ArticleId IdType="pubmed">31619481</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2016 Jul;132(1):145-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27206760</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2010 Apr;119(4):409-19</Citation><ArticleIdList><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2017 Apr;264(4):749-757</Citation><ArticleIdList><ArticleId IdType="pubmed">28220290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>